-
Sector Analysis
A Closer Look at the HTA Landscape in Oman, Saudi Arabia, and the UAE
Healthcare systems in the Gulf Cooperation Council (GCC)—comprised of Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates (UAE)—are the most developed in the Middle East region. Driven by rapid population growth, the GCC governments have made—and continue to make—significant investments for transformation in the healthcare sector, while simultaneously introducing cost-containment measures to control healthcare spending. As the value of reimbursed health technologies increases, the governments are increasingly becoming more reliant on economic evaluations or health technology assessments...
-
Product Insights
Neurogenic Orthostatic Hypotension (nOH): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Neurogenic Orthostatic Hypotension (nOH) - Global Clinical Trials Review, 2025" provides an overview of Neurogenic Orthostatic Hypotension (nOH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Neurogenic Orthostatic Hypotension (nOH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Gouty Arthritis (Gout): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Gouty Arthritis (Gout) - Global Clinical Trials Review, 2025" provides an overview of Gouty Arthritis (Gout) Clinical trials scenario. This report provides top line data relating to the clinical trials on Gouty Arthritis (Gout). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Dystrophic Epidermolysis Bullosa: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Dystrophic Epidermolysis Bullosa - Global Clinical Trials Review, 2025" provides an overview of Dystrophic Epidermolysis Bullosa Clinical trials scenario. This report provides top line data relating to the clinical trials on Dystrophic Epidermolysis Bullosa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Thrombotic Microangiopathy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Thrombotic Microangiopathy - Global Clinical Trials Review, 2025" provides an overview of Thrombotic Microangiopathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Thrombotic Microangiopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Chronic Pancreatitis: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Chronic Pancreatitis - Global Clinical Trials Review, 2025" provides an overview of Chronic Pancreatitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Pancreatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Systemic Sclerosis (Scleroderma): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Systemic Sclerosis (Scleroderma) - Global Clinical Trials Review, 2025" provides an overview of Systemic Sclerosis (Scleroderma) Clinical trials scenario. This report provides top line data relating to the clinical trials on Systemic Sclerosis (Scleroderma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Diabetic Peripheral Neuropathy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Diabetic Peripheral Neuropathy - Global Clinical Trials Review, 2025" provides an overview of Diabetic Peripheral Neuropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Cholera: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Cholera - Global Clinical Trials Review, 2025" provides an overview of Cholera Clinical trials scenario. This report provides top line data relating to the clinical trials on Cholera. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Autism Spectrum Disorder: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034
This report covers the 7MM and provides an Excel-based forecast model for the Autism Spectrum Disorder market through 2034. The autism market is crowded with inexpensive generic products and off-label drugs.There are currently no approved therapies to target the core symptoms of ASD, warranting targeted drug development. In the late-stage pipeline (Phase IIb onwards), there are three products being developed to target the core symptoms of ASD. The ASD market across the 7MM was valued at $364.9 million in the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.